Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 17, 2022 07:00 ET
|
Cabaletta Bio
– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific...
U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
March 01, 2022 08:00 ET
|
Cabaletta Bio
– Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis – PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE)...
Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference
February 28, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
January 11, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
January 03, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
December 14, 2021 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Participate in Upcoming Investor Conferences in November
November 09, 2021 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer
November 09, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...